BlossomHill Therapeutics (BLSM) has upcoming FDA regulatory milestones for BH-501284. The table below outlines estimated target dates and event types for these pending regulatory actions.
This section highlights FDA-related milestones and regulatory updates for drugs developed by BlossomHill Therapeutics (BLSM).
Over the past two years, BlossomHill Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
BH-30643 and BH-501284. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
BH-30643 FDA Regulatory Timeline and Events
BH-30643 is a drug developed by BlossomHill Therapeutics for the following indication: Treatment of Advanced EGFR C797S-positive NSCLC.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BH-30643
- Announced Date:
- November 9, 2026
- Indication:
- Treatment of Advanced EGFR C797S-positive NSCLC
Announcement
BlossomHill Therapeutics, Inc. announced the outcome of its End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding BH-30643 for the treatment of patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC).
Read Announcement- Drug:
- BH-30643
- Announced Date:
- September 15, 2026
- Indication:
- Treatment of Advanced EGFR C797S-positive NSCLC
Announcement
BlossomHill Therapeutics, Inc. announced updated data from the ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer (NSCLC) patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S.
AI Summary
BlossomHill Therapeutics reported updated results from its ongoing Phase 1/2 SOLARA trial of BH-30643 in people with non-small cell lung cancer (NSCLC) whose tumors developed the EGFR C797S resistance mutation after earlier EGFR inhibitor treatment. Among 40 patients, 45% had a tumor response, including 16 confirmed partial responses and two responses still being assessed. Disease was controlled in 88% of patients. At follow-up, 63% remained on treatment; median follow-up was 6.9 months. Some patients also had the T790M mutation.
Patients had received a median of two prior treatment lines, and nearly all had taken osimertinib. The results are encouraging for this difficult-to-treat group, which has no approved targeted therapy for this resistance mutation. Across 174 patients treated at expansion doses, treatment-related dose reductions occurred in 9%, and discontinuations in 3%. The company plans to begin a global Phase 2 study in C797S-positive NSCLC in early 2027. The findings are interim, and further study is needed to confirm BH-30643’s benefits and risks.
Read Announcement- Drug:
- BH-30643
- Announced Date:
- September 1, 2026
- Indication:
- Treatment of Advanced EGFR C797S-positive NSCLC
Announcement
BlossomHill Therapeutics, Inc. announced that updated data from the ongoing Phase 1/2 SOLARA trial describing anti-tumor activity of BH-30643 in patients with secondary epidermal growth factor receptor (EGFR) resistance mutations such as EGFR C797S will be shared as a mini-oral presentation on September 15, 2026 at the 2026 World Conference on Lung Cancer in Seoul, South Korea.
AI Summary
BlossomHill Therapeutics will present updated results from its ongoing Phase 1/2 SOLARA trial at the 2026 World Conference on Lung Cancer in Seoul, South Korea. The mini-oral presentation, scheduled for September 15, will describe the anti-tumor activity of BH-30643 in people with EGFR-mutant non-small cell lung cancer who have developed secondary resistance mutations, including EGFR C797S.
C797S can emerge after treatment with newer EGFR inhibitors such as osimertinib, and the company says no approved oral targeted treatments are available for this group. BlossomHill reports that early signs of tumor activity have been seen across different C797S co-mutations and treatment histories. The updated presentation will include longer follow-up, which may help clarify the drug’s clinical profile. BH-30643 is an investigational oral medicine being studied in SOLARA, a global trial evaluating its safety and potential effectiveness. The trial includes groups with different mutations and treatment histories. The findings are preliminary, and further study is needed to understand the drug’s benefits and risks.
Read Announcement- Drug:
- BH-30643
- Announced Date:
- August 18, 2026
- Indication:
- Treatment of Advanced EGFR C797S-positive NSCLC
Announcement
BlossomHill Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BH-30643 for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC) after prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI).
AI Summary
The U.S. Food and Drug Administration has granted Fast Track designation to BlossomHill Therapeutics’ investigational drug BH-30643. It is being developed for adults with advanced or metastatic non-small cell lung cancer that has an EGFR C797S mutation and has progressed after treatment with a third-generation EGFR inhibitor. The company says there are no approved oral targeted therapies for this group.
BH-30643 is designed to block mutant forms of EGFR, including the C797S mutation linked to treatment resistance. It is being studied in SOLARA, a global Phase 1/2 trial with more than 40 sites in 10 countries. The study includes patients who have and have not received prior EGFR inhibitor treatment.
Fast Track status allows more frequent discussions with the FDA and may permit rolling review of a future drug application. The medicine could also qualify for other expedited programs if it meets their requirements. The designation does not guarantee faster approval or prove that BH-30643 is safe or effective; it remains under clinical study.
Read Announcement
BH-501284 FDA Regulatory Events
BH-501284 is a drug developed by BlossomHill Therapeutics for the following indication: Novel Pan-KRAS Inhibitor.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- BH-501284
- Announced Date:
- September 28, 2026
- Target Action Date:
- Q1 2027
- Estimated Target Date Range:
- January 1, 2027 - March 31, 2027
- Indication:
- Novel Pan-KRAS Inhibitor
Announcement
BlossomHill Therapeutics, Inc. announced that the IND submission in Q1 2027
AI Summary
BlossomHill Therapeutics presented preclinical findings for BH-501284 at the AACR Conference on Pancreatic Cancer in San Diego, held September 25–28, 2026. The investigational oral drug is a non-covalent, pseudo-irreversible pan-KRAS inhibitor built on a novel Switch-II scaffold. It is designed to bind mutant KRAS for an extended period while sparing related HRAS and NRAS proteins.
In laboratory studies, BH-501284 remained bound to KRAS G12D for more than 54 hours and prolonged KRAS pathway inhibition in mutant cancer cells. In animal tumor models of pancreatic, lung and colorectal cancers, it produced tumor regression, including deeper and longer-lasting responses than tricomplex RAS inhibitors in a KRAS G12D pancreatic model. Combining it with anti-PD-1 treatment also extended survival in a colorectal cancer model compared with either treatment alone.
The company said these findings support advancing BH-501284 toward an investigational new drug application submission in the first quarter of 2027. The results are preclinical and do not establish safety or effectiveness in people.
Read Announcement- Drug:
- BH-501284
- Announced Date:
- September 28, 2026
- Indication:
- Novel Pan-KRAS Inhibitor
Announcement
BlossomHill Therapeutics, Inc announced the presentation of preclinical data on BH-501284 at the American Association for Cancer Research (AACR) Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development, taking place September 25-28, 2026, in San Diego, CA..
AI Summary
BlossomHill Therapeutics presented preclinical findings for BH-501284 at the AACR Conference on Pancreatic Cancer in San Diego, held September 25–28, 2026. The investigational oral drug is a non-covalent, pseudo-irreversible pan-KRAS inhibitor built on a novel Switch-II scaffold. It is designed to bind mutant KRAS for an extended period while sparing related HRAS and NRAS proteins.
In laboratory studies, BH-501284 remained bound to KRAS G12D for more than 54 hours and prolonged KRAS pathway inhibition in mutant cancer cells. In animal tumor models of pancreatic, lung and colorectal cancers, it produced tumor regression, including deeper and longer-lasting responses than tricomplex RAS inhibitors in a KRAS G12D pancreatic model. Combining it with anti-PD-1 treatment also extended survival in a colorectal cancer model compared with either treatment alone.
The company said these findings support advancing BH-501284 toward an investigational new drug application submission in the first quarter of 2027. The results are preclinical and do not establish safety or effectiveness in people.
Read Announcement